According to a new report published by Allied Market Research, titled, "World Radiopharmaceuticals Market - Opportunities and Forecasts, 2014-2022", the world radiopharmaceuticals market is expected to generate revenue of $8,207 million by 2022. The diagnostics segment held a dominant share in the world radiopharmaceuticals market in 2015, and is expected to maintain its lead during the forecast period. Asia-Pacific is projected to continue to dominate the market throughout the forecast period.

Key findings of the study: 

• Therapeutics segment is projected to be the fastest growing segment in the world radiopharmaceuticals market, registering a CAGR of 16.9% from 2016 to 2022.




• SPECT modality segment is expected to dominate the world radiopharmaceuticals market in 2015 and expected to retain its position throughout the study period.




• Thyroid application segment is expected to exhibit double-digit CAGR of 11%.




• Oncology application segment is expected to continue to lead the world radiopharmaceuticals market, accounting for close to 60% share by 2022.




• Asia-Pacific is projected to be the fastest growing radiopharmaceuticals market, registering a CAGR of 8.4%.

To read more please visit: http://finance.yahoo.com/news/radiopharmaceuticals-market-reach-8-207-130000977.html

Source: PRNewswire